HER2 overexpression and amplification is rare in ILC.3,24,25 In the study done by Porter et al, none of the 62 ILC cases studied showed positivity to HER2.25 Our findings of 5.9% of ILC versus 23.9% of IDC positivity to HER2 are comparable to the reported figures by Rakha et al, which showed 4% versus 23% in ILC and IDC; respectively.3 Others also reported HER2 gene amplification or overexpression in 3–5% of ILC.26 Worse prognosis is associated with HER2 positivity as it is considered as independent prognostic factor in BC in general and in ILC in particular.26 Here, ERBB2 is linked to breast cancer.